Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Neuralstem — Investor Presentation (June 2018)
25 slides from Palisade Bio's investor presentation, Jun 8, 2018
Slide 1: Corporate Overview
Corporate Overview NEURALSTEM INC | June/2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement ‘Safe Harbor statements under the Private Secures Ltigation Reform Act of 1995: This presentation contains forwardooking satements as defined in Section 27A of the Securties Act of 1993 as amended, and section 21€ of the Secures Exchange Act of 4934, a8 amended. Such forward-lo
Slide 3: Topics
Topics Highlights @ Platform/Pipeline NSI-189: Major NSI-566: ALS, Stroke, Depressive Disorder eSCl ‘Overview Cinical Resuts oe Management x xX) HB NEURALSTEM INC cots
Slide 4: 1. Highlights: Lead Programs
1. Highlights: Lead Programs NSI-189: MDD — Pro-cognitive, neurogenic small molecule —- Positive, randomized placebo-controlled Phase 1b in MDD - Phase II double-blind exploratory study in major depressive disorder (MDD) + Key Results: = Missed the Primary Endpoint: Montgomery-Asberg Depression Rati
Slide 5: 2. The Neuralstem Pipeline
NSI-189 NSI-566 2. The Neuralstem Pipeline jor Depressive Disorder (0) LongtermFolow. up ‘Study MOO) Cognition & Depression Cognition & Motor Recovery Enhanced Recovery ‘Type 1 &2 Diabetes rested Nevropaty Prevention /Reversal of Neuropathy \adatonsnduced Cogntve efit [Neuroprotection from Brain jun
Slide 6: 3. NSI-189: Pro-Cognitive Drug for Major Depressive Disorder
Slide 7: Phase 2a Mono-Therapy of Recurrent MDD
Phase 2a Mono-Therapy of Recurrent MDD Study Design Sequential Comparison Parallel Design Screening period: 14-28 days period: 12 wks, sments performed Long-Term follow-up study): 24 we durability (open label, al subjects discontinue treatment
Slide 8: MDD Phase 2a Study Results
MDD Phase 2a Study Results No 0.19 MADRS (Primay)—_Yes/es No 035 HaMD.7 Yesfes No 033 No 038 QIDS-SR (patient p=0.040 reported)* Yes!No (Stage 2 ony) 0.68 No 039 ‘SDQ (patient reported)* Yes/No p=0.084 0.64 No 020 PQ patent reported)* Yes/No 70.035 0.47 No 010 si YesMes(2") Trend p=.148 0.58 Trendp-
Slide 9: Effect of NSI-189 on Recurrent MDD
Effect of NSI-189 on Recurrent MDD Working Memory” Memory" Reaction Accuracy Reaction Speed (stage) Mental Flexibility cPFQ* $DQ-0utlook* SDQ-Depression* HAMD-6 Anxiety HAM D-6 Depression HAM D-17 MADRS-6 MADRS-10 Stage 2 Cohen's d <== Improvement Hl 40mg HH t0mg
Slide 10: Summary MDD Phase 2a Study -- Efficacy
Summary MDD Phase 2a Study -- Efficacy * NSI-189 showed significant improvement in cognitive functioning & patient-reported depression following 6-weeks of treatment. * CogScreen-MDD measures of processing speed, working memory, executive functioning, and negative feedback, were found to be relative
Slide 11: Summary MDD Phase 2a Study -- Safety
Summary MDD Phase 2a Study -- Safety Side effects: Fewer subjects than the placebo with symptoms and signs associated with MDD Vital Signs: No clinically meaningful changes in body weight or BMI + ECG: No clinically significant changes + Sexual Functioning Inventory: No clinically meaningful changes
Slide 12: NSI-189 Pre-clinical Data
Slide 13: Pre-clinical Overview
Pre-clinical Overview Restores LTPofAngelman Syndrome mouse brain Enhances short-term and long-term potentiation of normal mouse brain Enables faster, better, durable recovery after ischemic stroke in rat, increased neurogenesis and synaptic remodeling Ameliorates cognitive deficit in radiation-inju
Slide 14: NSI-189 Enhances Synaptic Plasticity
NSI-189 Enhances Synaptic Plasticity cognition = memory LIPis a cellular biomarker ofmemory ‘TBS after 2.5 hincubation TBS after 3.5 hincubation short- and long-term Nn of normal mouse es (n=8) Effect increases with exposure time and concentration, Time niny 7 ime Gin) <AS <Wrvehide —ASwsii89 tT Res
Slide 15: 4. NSI-566: ALS, Stroke & Chronic Spinal Cord Injury
Slide 16: Cell Therapy: Targeting Paralysis
Cell Therapy: Targeting Paralysis Status-Objective NSI-566 me al evel [Pores in| Pare coca — eas = (ChronieSpinal Cord inary —=s | Targeting Paralysis — ALS Phase 1 & 2 (n=30) : demonstrates preliminary clinical benefit against historical data. Ready for Ph2b/3 study — cStroke Phase | (n=9) : demons
Slide 17: NSI-566: Targeting Paralysis — Program Overviews
NSI-566: Targeting Paralysis — Program Overviews ALS Ischemic Stroke Chronic Spinal Cordinjury MARKET CONSIDERATIONS MARKET CONSIDERATIONS MARKETCONSIDERATIONS ~ Orphan condition = 1.8 milion with paralysis due to stroke in | | - 15 milion vith paralysis due to spinal ~ NSI-566 granted orphan status
Slide 18: Phase I & ambulatory, non-bulbar subjects
Phase | & 2 ambulatory, non-bulbar subjects vs. CEF matches Time to Death or ‘Motor Subscale <6
Slide 19: NSI-566: Subacute SCI - Restorative Effect in Monkey Model
NSI-566: Subacute SCI - Restorative Effect in Monkey Model
Slide 20: NSI-566: Chronic SCI--Phase I Human Safety Trial
NSI-566: Chronic SCI--Phase I Human Safety Trial Results from Curtis et al. (2018) Cell Stem Cell 22, 941-950 | Subject 001 | subject 006___|subjectoos__ | subject 010__| ISNCSCI Neurological Level jeans | Right Motor Ea |—Senzertet_| Left jae change T7>>17 T7>>17 T8>>T8 T8>>17 ND No change Neuropat
Slide 21: NSI-566: Chronic Stroke--Phase I Data at Months
NSI-566: Chronic Stroke--Phase I Data at 12 Months FughMeyer Motor Score Post Teatnieit ignths, 0-12) " [NIH Stroke Scale ‘Modified Rankin Scale KS To Le | Post Treatmiit (riGnths, 0-12) Post Treatment (iiGnths, 0-12) 'NSLS66: Phase 1 open-label, non-GCP dose-escalaton, feasibility & safety study fo
Slide 22: NSI-566: Chronic Stroke--Phase I Data at Months
NSI-566: Chronic Stroke--Phase I Data at 12 Months Engraftment over Time
Slide 23: NSI-566: CMC - Ready for commercialization
NSI-566: CMC - Ready for commercialization Chemically defined culturesystem — No serum, no feeder cells, no undefined raw material —- Fully tested for potential pathogens — Multi-tiered CGMP cell banks Efficientexpansion - Astable, multipotent stem cell line, no genetic manipulation — 1018- fold exp
Slide 24: 5. Financials
5. Financials ‘Total current assets 10,208,615 ‘Total assets Ss 11,549,998 LIABILITIES AND STOCKHOLDERS’ EQUITY, Preferred stock, 7,000,000 shares authorized, $0.01 par value; 1,000,000 shares. issued and outstanding at both March 31, 2018 and December 31, 2017 10,000 ‘Total abilities and stockholde
Slide 25: 6. Management
6. Management 25+ years of Pharma & Astrazenecd? Richard Daly biotech leadership Chief Executive experience; start up, : ; Officer & actingCFO | Seale up and D Bristol Myers Squibb transformations Karl Johe, Ph.D. Chief Scientific Officer Discoverer of neural stem cells and neurogenic ‘molecules, co